SensorMedics HFOV Mortality Advantage Merits Approval - Respiratory Panel
This article was originally published in The Gray Sheet
Executive Summary
A clear mortality benefit at 30 days and six months for SensorMedics' 3100B high-frequency oscillatory ventilator (HFOV) system compared to conventional ventilators warrants FDA approval, an agency advisory panel recommended July 16.